CARsgen announces the publication of its 7×21 CAR-T technology in Clinical Cancer Research titled "Coexpression of IL-7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion." clincancerres.aacrjournals.org/content/early/…

National Medical Products Administration (NMPA) has cleared CARsgen's IND application for the first-in-class drug candidate CT041, autologous CAR T cells for the treatment of claudin18.2-positive solid tumors. prnewswire.com/news-releases/…

We're presenting data for our anti-BCMA #CARTcell therapy at ASH in December #CARTcells #immunotherapy #CellTherapy #multiplemyeloma prnewswire.com/news-releases/…

ICYMI: We presented data for CT053, our anti-BCMA #CARTcell therapy at ASH 2020 #CARTcells #immunotherapy #CellTherapy #multiplemyeloma shorturl.at/xHY59

#CARsgen published phase 1 interim results for our claudin18.2-specific #CARTcells in gastrointestinal cancers

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology prnewswire.com/news-releases/…

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline prnewswire.com/news-releases/…

The successful release of the first U.S. patient product at the RTP GMP Manufacturing Facility is a remarkable milestone! businesswire.com/news/home/2022…

At the 7th Annual CAR-TCR Summit, in Boston, Massachusetts, CARsgen gave an oral presentation on the North America Phase 2 clinical trial of zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053). businesswire.com/news/home/2022…

We are delighted that the New Drug Application (NDA) for zevor-cel, a BCMA CAR T-cell fully developed in house by CARsgen, has been accepted by National Medical Products Administration. en.prnasia.com/releases/globa…

We are very happy to have Dr. Peltier join CARsgen! en.prnasia.com/releases/globa…

At the 2022 American Society of Hematology Annual Meeting, CARsgen presented a poster with the results of the phase II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel in Chinese patients with relapsed/refractory multiple myeloma. en.prnasia.com/releases/globa…

CARsgen's latest study (together with the State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute) published in Molecular Therapy. ttps://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(22)00713-4.pdf#%20

Today we announced a collaboration for the commercialization of CARsgen's BCMA CAR-T product CT053 in mainland China. prnewswire.com/news-releases/…

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI prnewswire.com/news-releases/…

We are glad to work with Roche, a global leader in oncology, to explore the potential of AB011 in combination with atezolizumab and chemotherapy for the treatment of gastric cancer. en.prnasia.com/releases/globa…

CARsgen Announced 2022 Annual Results and Business Updates en.prnasia.com/releases/globa…

CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer en.prnasia.com/releases/globa…

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer en.prnasia.com/releases/globa…

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S. en.prnasia.com/releases/globa…